Video Series

Specialists discuss unmet needs that continue to exist in treating patients with NSCLC despite advances in treatment, and how these impact patient outcomes.

Russell P. Gollard, MD, FACP, discusses ways to ensure access to appropriate treatment for rare diseases like hemophilia A, such as finding motivated providers with expertise and using utilization management strategies for cutting-edge care to bridge the gap between available community treatments and emerging therapies, ultimately benefiting patients.

Heart failure treatment strategies are emphasized based off recent clinical trial data.

Utilization of the four pillars in heart failure therapy are highlighted as aggressive first-line treatment strategies.

Insight surrounding the switch from reference drugs to biosimilars is provided by Bincy Abraham, MD, MS.

Vibeke Strand, MD, evaluates implementation of biosimilars in patients with no history of reference biologic use.

Cost-effectiveness considerations are highlighted by Dr Abou-Alfa.

Treatment continuity and adherence in HCC can be encouraged through patient education and engagement.

Patrick Forde, MBBCh, discusses ALK rearrangement in NSCLC and highlights ALINA trial results from ESMO 2023.

An expert comparison of recent data on neoadjuvant and perioperative immunotherapy in resectable early-stage NSCLC, including CheckMate 77T, CheckMate-816, and KEYNOTE-671.

Patrick Forde, MBBCh, shares insights on perioperative immunotherapy in the CheckMate-77T study presented at ESMO 2023.

Specialists assess the pros and cons of using immunotherapy in managing metastatic non–small cell lung cancer and delve into dosage variations and considerations when choosing different immunotherapy types.

Panelists discuss balancing aggressive treatment strategies and maintaining the patient’s quality of life.

Russell P. Gollard, MD, FACP, analyzes the role of ICER reports in optimizing patient care and health care costs.

Therapy strategies in the management of heart failure are discussed.

The role of the primary care physician (PCP) in heart failure management is explored.

Panelists discuss reference biologic and biosimilar concentrations as well as the importance of citrate-free, less frequent injectable medications.

Experts compare approaches to prescribing biosimilars over reference drugs.

The panelists discuss breakthrough technologies that are revolutionizing mCRC diagnosis.

Medical experts discuss precision medicine and targeted therapies driving the management of metastatic colorectal cancer treatment.

Joseph M. Coney, MD, FACS, explores strategies to address treatment obstacles among vulnerable patients and examines the effects of step therapy and prior authorization within a complex health care landscape.

Experts discuss the current standard treatment options for patients diagnosed with metastatic NSCLC (mNSCLC).

Specialists review specific prognostic factors and biomarkers that help guide treatment selection for patients with metastatic NSCLC (mNSCLC) and discuss if these biomarkers differ from those observed in early-stage NSCLC.

Russell P. Gollard, MD, FACP, discusses coverage decisions for expensive treatments in hemophilia, including total cost of care, drug availability, and real-world evidence.

Key opinion leaders hold a discussion highlighting significant factors in heart failure staging.

A panel of medical experts discuss various categories of heart failure and their clinical implications.

Providers speak to the importance of being knowledgeable of efficacy and safety data before prescribing biosimilars to patients.

Clinical and social challenges associated with biosimilars are discussed by key opinion leaders.

An overview of the HIMALAYA study and IMbrave150 trial are provided.

Medical experts discuss patient considerations when utilizing clinical pathways in HCC treatment.